Menu Search
Equities

Bio-Techne Corp

  • Add to watchlist
  • Add to portfolio
  • Add an alert
TE1:DUS

Bio-Techne Corp

Actions
  • Price (EUR)54.50
  • Today's Change-3.00 / -5.22%
  • Shares traded300.00
  • 1 Year change-23.78%
  • Beta1.4488
Data delayed at least 15 minutes, as of Feb 06 2026 07:11 GMT.
More ▼
Notice
Important Notice
Please note that effective 5th February, 2026 the Financial Times will no longer publish or present securities from the Nairobi Stock Exchange.

Profile data is unavailable for this security.

About the company

Bio-Techne Corporation develop, manufacture and sell life science reagents, instruments and services for the research, diagnostics and bioprocessing markets worldwide. The Company’s segments include Protein Sciences segment and Diagnostics and Spatial Biology segment. The Protein Sciences segment is a developer and manufacturer of biological reagents used in all aspects of life science research, diagnostics and cell and gene therapy. The Diagnostics and Spatial Biology segment develops and manufactures diagnostic products, including controls, calibrators, and diagnostic assays for the regulated diagnostics market, advanced tissue-based in-situ hybridization assays and instrumentation for spatial genomic and tissue biopsy analysis and genetic and oncology kits for research and clinical applications. Its product portfolio and application enable scientific investigations into biological processes and molecular diagnostics and progression of specific diseases.

  • Revenue in USD (TTM)1.22bn
  • Net income in USD79.96m
  • Incorporated1981
  • Employees3.10k
  • Location
    Bio-Techne Corp614 Mckinley Pl N E, Suite 1500MINNEAPOLIS 55413United StatesUSA
  • Phone+1 (612) 379-8854
  • Fax+1 (612) 656-4400
  • Websitehttps://www.bio-techne.com/
More ▼
Data Provided by LSEG
All markets data located on FT.com is subject to the FT Terms & Conditions
All content on FT.com is for your general information and use only and is not intended to address your particular requirements. In particular, the content does not constitute any form of advice, recommendation, representation, endorsement or arrangement by FT and is not intended to be relied upon by users in making (or refraining from making) any specific investment or other decisions.
Any information that you receive via FT.com is at best delayed intraday data and not "real time". Share price information may be rounded up/down and therefore not entirely accurate. FT is not responsible for any use of content by you outside its scope as stated in the FT Terms & Conditions.